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Abstract
Background: The World Health Organization has estimated that by 2030, chronic obstructive pulmonary disease
will be the third leading cause of death worldwide. Most knowledge of chronic obstructive pulmonary disease is
based on studies performed in Europe or North America and little is known about the prevalence, patient
characteristics and change in lung function over time in patients in developing countries, such as those of Latin
America. This lack of knowledge is in sharp contrast to the high levels of tobacco consumption and exposure to
biomass fuels exhibited in Latin America, both major risk factors for the development of chronic obstructive
pulmonary disease. Studies have also demonstrated that most Latin American physicians frequently do not follow
international chronic obstructive pulmonary disease diagnostic and treatment guidelines. The PRISA Study will
expand the current knowledge regarding chronic obstructive pulmonary disease and risk factors in Argentina, Chile
and Uruguay to inform policy makers and health professionals on the best policies and practices to address this
condition.
Methods/Design: PRISA is an observational, prospective cohort study with at least four years of follow-up. In the
first year, PRISA has employed a randomized three-staged stratified cluster sampling strategy to identify 6,000
subjects from Marcos Paz and Bariloche, Argentina, Temuco, Chile, and Canelones, Uruguay. Information, such as
comorbidities, socioeconomic status and tobacco and biomass exposure, will be collected and spirometry,
anthropometric measurements, blood sampling and electrocardiogram will be performed. In year four, subjects will
have repeat measurements taken.
Discussion: There is no longitudinal data on chronic obstructive pulmonary disease incidence and risk factors in
the southern cone of Latin America, therefore this population-based prospective cohort study will fill knowledge
gaps in the prevalence and incidence of chronic obstructive pulmonary disease, patient characteristics and changes
in lung function over time as well as quality of life and health care resource utilization. Information gathered
during the PRISA Study will inform public health interventions and prevention practices to reduce risk of COPD in
the region.
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Although chronic pulmonary diseases, including chronic
obstructive pulmonary disease (COPD), are believed to
be one of the leading causes of morbidity and mortality
in the Southern cone, few studies have described the
prevelance and patient characteristics in this region and
no study has described COPD trends over time. The
World Health Organization (WHO) has predicted a rise
in the mortality from COPD, from the fourth leading
cause of death in 2004 to the third in 2030, largely attri-
butable to rising tobacco consumption and biomass fuel
exposure, both major risk factors for COPD and over-
whelmongly prevalent in developing countries[1-3].
Variable definitions, under-recognition and under-
d i a g n o s i so fC O P Da n di t se x a c e r b a t i o n sh a v em a d ei t
difficult to quantify prevalence, morbidity and mortality
based on available data, particularly in low and middle-
income countries[4,5]. An accurate estimate of the
worldwide burden of COPD remains unknown[6,7]. The
Latin American Project for the Investigation of Obstruc-
tive Lung Disease (PLATINO) examined the prevalence
of COPD by pre- and post-bronchodilator spirometry
among persons over age 40 in five major Latin Ameri-
can cities and found that the overall prevalence (95%
C I )o fC O P Dv a r i e df r o m7 . 8 %( 5 . 9 - 9 . 7 )i nM e x i c oC i t y
to 19.7% (17.2-22.1) in Montevideo and was notably
higher in older subjects and males. The reasons for the
range of prevalence are unclear[8]. Outside of this study,
the reliability of COPD prevalence estimates is question-
able. For example, there are no population-based studies
of COPD prevalence in Argentina, but estimated preva-
lences range from 5 to 8%[9]. Interestingly, these num-
bers are lower than the prevalences demonstrated by the
PLATINO study, and Argentine adults have among the
highest mean tobacco consumption in the region (58.1
pack-years)[5].
Moreover, studies have shown rates of tobacco con-
sumption amongst younger generations in Latin Amer-
ica to be shocking. For example, in Argentina, Chile and
Uruguay, 25.8%, 39.2% and 22.9%, respectively, of 15-18
years olds smoke compared with WHO estimates of
13.2% of people aged 15-18 worldwide[10-12]. These
numbers support the idea that Latin America is early in
its COPD epidemic and the prevalence and associated
costs will only continue to rise as populations age,
unless appropriate preventive and treatment measures
are instituted.
In 2010, the National Heart, Lung and Blood Institute
(NHLBI) funded an observational prospective cohort
study, led by the Instituto de Efectividad Clinica y Sani-
taria (IECS) in Buenos Aires, Argentina in parnership
with Tulane University School of Public Health and
Tropical Medicine in New Orleans, Louisiana, U.S.A,
the Universidad de la Frontera in Temuco, Chile, and
the Universidad de la República, in Montevideo, Uru-
guay, to determine the prevalence and incidence of
COPD and describe patient characteristics and change
in lung function over time, as well as quality of life and
health care resources utilization. Spirometry will be per-
formed and questionnaires administered to 6,000 sub-
jects from Marcos Paz and Bariloche, Argentina,
Temuco, Chile, and Canelones, Uruguay to further
knowledge of COPD in these mid-sized cities represent-
ing the Southern cone of Latin America.
Methods/Design
The PRISA study is an observational, prospective cohort
study with at least 4 years of follow-up. Subjects 45-75
years of age are being recruited using a multistage clus-
ter sampling method. The study is composed of two
phases. In the first phase, baseline data will be collected
regarding exposure to risk factors and prevalence of
COPD. In the second phase, annual follow-up data will
be obtained to determine the rate of incident COPD,
the association between exposure and development of
COPD, and the rate of decline in lung function exhib-
ited by COPD subjects identified in the first phase.
Inclusion criteria were men and women aged 45-75
years of age, permanent resident at one of the study
locations for at least six months each year and willing-
ness to offer written consent. Exclusion criteria were an
expressed intenton to relocate within the next four
years, inability to respond to the questionnaire due to
cognitive impairment or language difficulty, active tuber-
culosis, pregnancy, or history of detached retina and
cardiac infarction or ocular, thoracic or abdominal sur-
gery within prior six weeks (contraindications to spiro-
metry testing). A total of 6,000 non-institutionalized,
mainly urban, (1,500 participants per site), men and
women will be recruited from Bariloche and Marcos
Paz, Argentina, Temuco, Chile, and Canelones, Uruguay.
Sampling Procedure
A randomized, three-staged, stratified, cluster sampling
strategy was usedin order to select a representative sam-
ple of the general population aged 45 to 75 years of age.
The first stage selected 60 census enumeration areas
using probability proportional to size, with implicit stra-
tification by socioeconomic level of the enumeration
area. The second stage selected 40 households from
each enumeration area using systematic sampling. The
third stage selected one household member between 45-
75 years of age for the study. The final sampling was
stratified by gender, with 50% men and 50% women,
and age distribution based on recent population census
data[13,14](Figure 1).
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Participants identified by the sampling procedure are
invited to participate through a letter from the site institu-
tion. The interviewer makes contact with the household
and arranges a home visit, to collect questionnaire data,
and a clinic visit. At the clinic visit, physical measure-
ments, pre and post-bronchodilator spirometry and elec-
trocardiogram (EKG) are performed and overnight, fasting
blood samples are collected. To minimize non-participa-
tion and the potential for bias in the results, specific mea-
sures, such as travel assistance or home assessment,
flexibility of appointment times, feedback of blood test
and examination results and participation of local health
professionals, non-governmental organizations and local
authorities, have been involved to facilitate and encourage
the participation of those selected for the study.
Primary Outcome
The primary outcome for phase one of the study is the
prevalence of COPD, as defined by the Global initiative
for Obstructive Lung Disease (GOLD). The lower limit of
normal (LLN) values for these populations will be calcu-
lated, using the American Thoracic Society (ATS) and
European Respiratory Society (ERS) guidelines. The pri-
mary outcome for the four-year follow-up is the change
in lung function. Secondarily, the incidence of COPD will
be calculated. These criteria are listed in Table 1.
Secondary Measures
The following measures will also be collected: socio-
demographic data including age, gender, education,
race, occupation, family income; type of health cover-
age and degree of health service utilization; history and
current status of tobacco, biomass fuel or occupational
exposures; level of alcohol consumption; physical activ-
ity including type, frequency and intensity; nutritional
intake; self-reported past medical history; pharmacolo-
gic and non-pharmacologic treatment received for
prior medical history; self-reported family history and
history of hospital admissions due to pulmonary dis-
ease during childhood. Blood pressure and anthropo-
metrics, including height, weight, abdominal and hip
circumference, will also be measured. Biochemical
measurements such as lipid profile, serum creatinine
and glucose will be conducted and EKG will be
performed.
Instruments
Information about current and former cigarette smok-
ing, including age at which smoking was initiated, years
of smoking, amount of cigarettes smoked per day, cessa-
tion attempts and treatments will be assessed by the
Global Adult Tobacco Survey (GATS)[15]. Use of other
forms of tobacco, exposure to passive cigarette smoking
and indoor pollution will also be assessed using other
questionnaires to assess indoor heating and cooking
using biomass fuels. Nutritional information will be col-
lected using a semi-quantitative food frequency ques-
tionnaire (FFQ) adapted from the National Cancer
Institute validated by our research team to be used in
Argentina, Chile and Uruguay[16]. Depression and anxi-
e t yw i l lb ea s s e s s e db yt h en i n ei t e mP a t i e n tH e a l t h
Questionnaire (PHQ-9)[17], which has been validated in
Argentina[18]. Traumatic, stressful events and spiritual-
ity will be assessed through the Hispanic Community
Health Study/Study of Latinos (HCHS/SOL) study ques-
tionnaire which has been cross-culturally adapted[19].
The International Physical Activity Questionnaire
(IPAQ)[20] will be used to assess physical activity. SF-12
[21] and European Quality of Life 5-Dimensions (EQ5D)
[22] questionnaires will be used to evaluate health-
related quality of life and social preferences, respectively
through locally validated versions of these tools[23,24].
The remainder of the questionnaires used to gather
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Figure 1 Sampling procedure.
Table 1 Spirometric criteria for the definition of COPD
Spirometry
Criteria
Definition
GOLD[1] Post-bronchodilator forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC) < 70 and FEV1 < 80% of
predicted value
ATS[28,29] Post-bronchodilator FEV1/FVC below the LLN and FEV1 < 100% of predicted value
ERS[30] Post-bronchodilator FEV1/FVC < 88% of the predicted value for men and < 89% for women
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adapted from the HCHS/SOL [19].
Spirometric measurements will be performed with
identical, portable, battery operated, ultrasound transit-
time based EasyOne
™ spirometers (Medical Technolo-
gies, Chelmsford, Massachusetts and Zürich, Switzer-
land). Calibration will be checked daily with a three-liter
syringe. Test results will be stored in the spirometer
memory and downloaded weekly to a central computer.
Trained professionals will first administer a question-
naire to determine patient eligibility, as described above.
Trained personnel will then perform spirometry follow-
ing ATS guidelines. Spirometry will be conducted with
subjects in the seated position, wearing a nose clip and
using a disposable mouthpiece. Subjects will perform up
to eight forced expiratory maneuvers with forced vital
capacity (FVC) and forced expiratory volume in the first
second (FEV1) reproducible within 150 ml. A beta-ago-
nist bronchodilator, Albuterol 200 ug, will be adminis-
tered and repeat spirometry will be performed 15
minutes later, using the same criteria. All field methods
have been tested in pilot studies at each site.
All health care professionals involved in the study have
participated in a two-day spirometry and questionnaire
training led by the main study coordinator, a pulmonolo-
gist from the coordinating center (E.S.). The spirometry
course focused on the acceptability and reproducibility of
a pulmonary function test and the factors associated with
an unacceptable spirometry test. The technicians were
certified if they were able to perform 10 pulmonary func-
tion tests that met the 2005 ATS/ERS criteria.
Statistical Analysis
Sample size
The calculated sample size is 6,000 participants (1,500
per site). This sample will be sufficient to provide pre-
cise estimates of the prevalence of COPD by gender and
site and associated risk factors, in three age-defined
categories: 45 to 54, 55 to 64 and 65 to 75 years old.
The proposed sample size is sufficient to comply with
the precision requirements of a complex sample that
assumes a design effect of 1.5 and the prevalence of risk
factors of interest of 5% or greater (Table 2). All power
calculations used a statistically significant alpha level of
0.05 and a statistical power of 85%, which will permit
detection of moderate and large relative risks.
Statistical Analysis
General characteristics of the population will be
described. For continuous variables, mean and median,
range, standard deviation, and/or quartile range will be
calculated according to the distribution of each variable.
In the case of categorical variables, absolute and relative
frequencies will be calculated.
In order to determine the prevalence and incidence of
COPD and patient characteristics and risk factors, the
design effect of the first stage unit of sampling will be
considered. Weighting will be based on the relation
between the number of individuals included in the study
and the population size and composition of each site
according to the most recent census data. Likewise, the
analysis will be carried out by socioeconomic strata,
gender and age categories.
To assess the association between risk factors and
COPD, linear regression and simple and multiple logisti-
cal regressions will be used according to the nature of
the response variables. Continuous variables that are not
normally distributed will be evaluated by the application
of transformations and categorizations wherever applic-
able[25]. The secular trends in risk factors over time
will be evaluated with methods of statistical analysis that
take into account the correlation between repeated mea-
sures. To evaluate the changes in risk factors over time
by sub-groups of interest, generalized estimation equa-
tions will be used. To estimate the rate of accumulated
COPD incidents, the Kaplan-Meir method will be used.
The log rank test will be used to compare the differ-
ences between the curves of accumulated incidence
events. The log rank test of trend will be applied to ana-
lyze the relationship between the accumulated risk by
quartile group or by created groups of interest. In order
to quantify the relationship between risk factors and the
incidence of COPD, the Cox Proportional Hazards
method will be used. Potential confounders and interac-
tions will be explored.
Appropriate diagnostics will be carried out to test
goodness of fit, co-linearity, and atypical observations in
each model. In all cases, fulfillment of assumptions in
the model by means of exploration of residual behavior
will be verified. Statistical analysis software STATA 10.0
and SAS 9.0 will be used[26,27].
Ethical Considerations
The protocol has obtained formal ethical approval from
the respective Institutional Review Boards in Argentina,
Table 2 Sample size for a highly complex study design
for effect and design of specific proportion
Proportion Design Effect
1.0 1.5 2.0 2.5 3.0
0.26-0.50 30 45 60 75 90
0.25 32 48 64 80 96
0.20 40 60 80 100 120
0.15 53 80 107 133 160
0.10 80 120 160 200 240
0.05 160 240 320 400 480
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follow guidelines for the protection of the rights of
human volunteers. All investigators and personnel in
the study have attended a training session regarding this
theme, certified by the NIH. All participants will sign
the informed consent during the initial visit. To protect
participant confidentiality, the information included in
database will not contain personal information. Each
participant in the study will be assigned a unique identi-
fication code (ID), which will not be a mathematical
derivation of the medical registration of the patient or
any other personal identifier.
All transmission of data obtained in the field, along
with the central lab results and the coordination of the
data will take place via a secure website requiring a
password for access. Blood samples will be stickered
with the ID only, to be transmitted and processed in the
central lab. No personal information of any type will be
in any presentation or publication. In addition, all study
personnel will sign a confidentiality agreement to not
divulge information or data related to the study.
Discussion
Despite the burden of COPD in Latin America, there is
limited knowledge of the prevalence and incidence of
COPD, patient characteristics and provider prescribing
regimens in this region. Although the PRISA study is
not representative of the total population in Latin
American, it is, to our knowledge, the first population-
based cohort study addressing knowledge gaps and
informing public health policy-making on the impact of
COPD in Argentina, Chile and Uruguay.
The close cooperation between experienced research-
ers in Argentina, Chile, Uruguay, and Tulane University
in the USA is a study strength. Methodology to estimate
prevalence is similar to that used in the PLATINO
study, which will allow comparison of data between the
Latin American countries studied in the PLATINO
s t u d ya n dt h eb a s e l i n ep h a s eo ft h eP R I S As t u d y .T h e
PRISA study, however, has the advantage of being the
first longitudinal study of pulmonary function in Latin
America. In addition, questionnaires used in the HCHS/
SOL study[19], a cohort study performed on Hispanic
population in the USA will be also used in the PRISA
study, allowing additional comparison between PRISA
study subjects and the Latin American and Hispanic
communities in the United States.
It is clear that chronic pulmonary diseases, including
COPD, are leading causes of morbidity and mortality
worldwide. Our study will provide important informa-
tion about the epidemiology of COPD in select cities in
Argentina, Chile and Uruguay. In the first phase of the
study, it will describe COPD prevalence and associated
risk factors, socioeconomic status, concurrent medical
history, patient characteristics and physician prescribing
trends. In the second phase, it will describe the decline
in lung function over time, COPD incidence and any
changes in patient characteristics and physician pre-
scribing trends. This information is paramount to the
development of appropriate public health legislation and
preventive interventions.
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